News for Cannara Biotech Inc. (LOVFF)

\n Cannara Biotech (TSXV: LOVE) (OTCQB: LOVFF) to release Q2 2025 financial results on April 28, 2025. Investors can participate in an earn

MONTREAL, April 16, 2025 (GLOBE NEWSWIRE) -- Cannara Biotech Inc. (â\u0080\u009cCannaraâ\u0080\u009d, â\u0080\u009cthe Companyâ\u0080\u009d, â\u0080\u009cusâ\u0080\u009d or â\u0080\u009cweâ\u0080\u009d) (TSXV: LOVE) ( LOVFF) (FRA: 8CB0),

**media[596622]**

**media[574693]**

**media[559080]**

**media[548533]**

MONTREAL, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Cannara Biotech Inc. (”œCannara”, ”œthe Company”, ”œus” or ”œwe”) (TSXV: LOVE) ( LOVFF) (FRA: 8CB0), a

Record Revenue: Net revenues of $25.1 million in Q1 2025, a 29% increase compared to $19.5 million in Q1 2024, driven by strong demand for Cannara's premium-gra

**media[493838]**

**media[490661]**

MONTREAL, Dec. 12, 2024 (GLOBE NEWSWIRE) —

**media[475799,475800,475801,475802,475803]**

Amid this slowdown, certain products capture consumer interest, even as prices stabilize and competition intensifies.

Gross cannabis revenues before excise taxes increased to $26.2 million in Q3 2024 from $20.6 million in Q3 2023, a $5.6 million or 27.6%, increase.

In a recent report, Pablo Zuanic of Zuanic & Associates analyzed trends in Canada's recreational cannabis market through May 2024. The report highlights a deceleration in market growth and notable shifts in sales dynamics among leading licensed producers (LPs).

Net revenue, increased to $19.7 million in Q2 2024 from $13.0 million in Q2 2023, a 51.0% increase. Gross profit, before fair value adjustments, increased to $7.1 million in Q2 2024 from $4.0...

Thanks in part to market share gains and increasing demand for high-quality cannabis at an affordable price in Canada, Cannara Biotech Inc. (OTCMKTS: LOVFF), the vertically integrated producer of premium-grade cannabis and derivative product offerings, reported record growth in revenue and net income for its fourth quarter of 2023.

Record Q4 and year end net revenues of $18.3 million and $57.6 million, representing a 53% and 60% increase compared to the same periods of 2022 Sequentially, Q4 showed significant growth over Q3...

Cannara Biotech Inc.